GRACEcast Radiation Oncology Video cancerGRACE - H. Jack West, MD
-
- Science
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
-
- video
Can we safely combine Tarceva with brain radiation for lung cancer with brain radiation?
Dr. Jack West describes a case series that illustrates the safety of giving whole brain radiation along with concurrent Tarceva (erlotinib) for patients with lung cancer and brain metastases.
-
- video
Is there an alternative to brain radiation for patients with several brain metastases?
Dr. Jack West reviews a case that illustrates the potential option of systemic therapy for brain metastases before initiating whole brain radiation.
-
- video
Refining Radiation Therapy for Lung Cancer, Part 6: Moving Radiation Developments into Metastatic Lung Cancer (video)
Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews the rationale and feasibility of using focal radiation in the setting of metastatic lung cancer.
-
- video
Refining Radiation Therapy for Lung Cancer, Part 5: New Techniques (video)
Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, describes new technologies that are improving the accuracy and safety of radiation for stage non-small cell lung cancer (NSCLC).
-
- video
Refining Radiation Therapy for Lung Cancer, Part 4: Defining a Role for SBRT (video)
Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, covers the benefits and limitations of stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC).
-
- video
Refining Radiation Therapy for Lung Cancer, Part 3: Recent Successes and Open Questions (video)
Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews recent successful experiences with stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer and reviews several open questions about this strategy.